Associated Papers
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
Punzi S et al.
Cells, 2019
31216647 (PubMed )
Supplement: cells-08-00605-s001.zip › cells-502088-SI › TableS2.xlsx › EXOME-seq_PDXs
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA et al.
Nature Communications, 2017
29192207 (PubMed )
Supplement: 41467_2017_1864_MOESM3_ESM.xlsx › MCF7-LTEDY537C
Identification of novel genetic loci GAL3ST4 and CHGB involved in susceptibility to leprosy.
Yuan Y et al.
Scientific Reports, 2017
Sacral agenesis: a pilot whole exome sequencing and copy number study.
Porsch RM et al.
Bmc Medical Genetics, 2016
28007035 (PubMed )
Supplement: 12881_2016_359_MOESM2_ESM.xlsx › all_variants
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.
Raaijmakers MI et al.
Oncotarget, 2016
27791198 (PubMed )
Supplement: oncotarget-07-77163-s002.xlsx › Patient_2_late_met_1
Whole-exome sequencing identifies Y1495X of SCN5A to be associated with familial conduction disease and sudden death.
Tan ZP et al.
Scientific Reports, 2014
25010007 (PubMed )
Supplement: srep05616-s2.xls › dominant_result_new
Select a paper to view details